In last trading session, Editas Medicine, Inc. (NASDAQ:EDIT) saw 1,600,731 shares changing hands with its beta currently measuring 2.09. Company’s recent per share price level of $32.16 trading at -$0.61 or -1.86% at ring of the bell on the day assigns it a market valuation of $2Billion. That closing price of EDIT’s stock is at a discount of -24.25% from its 52-week high price of $39.96 and is indicating a premium of 56.44% from its 52-week low price of $14.01. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.04 Million shares which gives us an average trading volume of 884.86 Million if we extend that period to 3-months.
For Editas Medicine, Inc. (EDIT), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.5. Splitting up the data highlights that, out of 11 analysts covering the stock, none rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 5 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.61 in the current quarter.
Editas Medicine, Inc. (NASDAQ:EDIT) trade information
In the face of being in the red today for losing -1.86%, in the last five days EDIT remained trading in the green while hitting it’s week-highest on Wednesday, Oct 14 when the stock touched $35.06- price level, adding 8.27% to its value on the day. Editas Medicine, Inc.’s shares saw a change of 8.61% in year-to-date performance and have moved 3.61% in past 5-day. Editas Medicine, Inc. (NASDAQ:EDIT) showed a performance of 2.65% in past 30-days. Number of shares sold short was 10.47 Million shares which calculate 0.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $41.75 to the stock, which implies a rise of 29.82% to its current value. Analysts have been projecting $28 as a low price target for the stock while placing it at a high target of $65. It follows that stock’s current price would jump +102.11% in reaching the projected high whereas dropping to the targeted low would mean a loss of -12.94% for stock’s current value.
Editas Medicine, Inc. (EDIT) estimates and forecasts
Statistics highlight that Editas Medicine, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added +38.32% of value to its shares in past 6 months, showing an annual growth rate of 0.37% while that of industry is 13.9. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -90.6% in the current quarter and calculating -2.7% decline in the next quarter. This year revenue growth is estimated to rise 32.7% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $6.36 Million for the same. And 7 analysts are in estimates of company making revenue of $5.93 Million in the next quarter that will end in December 01, 2020.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -46.8% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -14.6% while estimates for its earnings growth in next 5 years are of 0%
Editas Medicine, Inc. (NASDAQ:EDIT)’s Major holders
Insiders are in possession of 2.41% of company’s total shares while institution are holding 75.78% percent of that, with stock having share float percentage of 77.65%. Investors also watch the number of corporate investors in a company very closely, which is 291 institutions for Editas Medicine, Inc. that are currently holding shares of the company. ARK Investment Management, LLC is the top institutional holder at EDIT for having 7.55 Million shares of worth $223.21 Million. And as of June 29, 2020, it was holding 12.12% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 5.76 Million shares on June 29, 2020. The number of shares represents firm’s hold over 9.25% of outstanding shares, having a total worth of $170.39 Million.
On the other hand, ARK ETF Tr-ARK Innovation ETF and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of July 30, 2020, the former fund manager was holding 5712794 shares of worth $167.73 Million or 9.17% of the total outstanding shares. The later fund manager was in possession of 1.96 Million shares on August 30, 2020, making its stake of worth around $68.95 Million in the company or a holder of 3.14% of company’s stock.